Abstract
Objective:
In experimental animals, recent results suggest that the addition of inulin-type fructans such as oligofructose (OFS) in the diet decreases triacylglycerol accumulation in the liver tissue. Therefore, we have investigated the effect of daily ingestion of OFS in seven patients with nonalcoholic steatohepatitis (NASH), confirmed by liver biopsies.
Design:
They received 16 g/day OFS or maltodextrine (placebo) for 8 weeks in a randomized double-blind crossover design. Energy intake, body composition, liver steatosis and blood parameters were analysed after 4 and 8 weeks of dietary supplementation.
Results:
Compared to placebo, OFS decreased significantly serum aminotransferases, aspartate aminotransferase after 8 weeks, and insulin level after 4 weeks, but this could not be related to significant effect on plasma lipids.
Conclusion:
This pilot study supports the putative interest of OFS in the management of liver diseases associated with abnormal lipid accumulation in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agrawal S & Bonkovsky HL (2002): Management of nonalcoholic steatohepatitis: an analytic review. J. Clin. Gastroenterol. 35, 253–261.
Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP & Ellmerer M (2001): Central role of the adipocyte in the metabolic syndrome. J. Investig. Med. 49, 119–126.
Brighenti F, Casiraghi MC, Canzi E & Ferrari A (1999): Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal motility and blood lipids in healthy male volunteers. Eur. J. Clin. Nutr. 53, 726–733.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA & Bacon BR (1999): Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467–2474.
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M & George J (2002): NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373–379.
Daubioul CA, Rousseau N, Demeure R, Gallez B, Taper HS, Declerck B & Delzenne NM (2002): Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. J. Nutr. 132, 967–973.
Daubioul CA, Taper HS, De Wispelaere LD & Delzenne NM (2000): Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese Zucker rats. J. Nutr. 130, 1314–1319.
Delzenne NM & Williams CM (2002): Prebiotics and lipid metabolism. Curr. Opin. Lipidol. 13, 61–67.
Diraison F, Moulin P & Beylot M (2003): Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non alcoholic fatty liver disease. Diabetes Metab. 29, 478–485.
Jackson KG, Taylor GR, Clohessy AM & Williams C (1999): The effect of daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br. J. Nutr. 82, 23–30.
Kok N, Roberfroid M & Delzenne N (1996): Dietary OFS modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 45, 1547–1550.
Letexier D, Diraison F & Beylot M (2003): Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J. Clin. Nutr. 77, 559–564.
Luyck FH, Lefebvre PJ & Scheen AJ (2000): Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 26, 98–106.
Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P & Rizzetto M (2002): Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome : further evidence for an etiologic association. Hepatology 35, 367–372.
Reid AE (2001): Nonalcoholic steatohepatitis. Gastroenterology 121, 710–723.
Roberfroid MB & Delzenne NM (1998): Dietary fructans. Annu. Rev. Nutr. 18, 117–143.
Yu AS & Keeffe EB (2002): Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord. 2, 11–19.
Zafrani ES (2004): Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 444, 3–12.
Acknowledgements
We thank all the subjects who participated in this study, and MA Bioul for her technical assistance; N Rousseau and G Catillon for their help in patient anamnesis, and Orafti (Tienen Belgium) for their help in preparing the samples.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guarantor: NM Delzenne.
Contributors: CAD has performed all analysis and has written the first draft of the paper with NMD. YH and ED have managed the clinical follow-up of the patients. PL has performed the statistical analysis.
Rights and permissions
About this article
Cite this article
Daubioul, C., Horsmans, Y., Lambert, P. et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 59, 723–726 (2005). https://doi.org/10.1038/sj.ejcn.1602127
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejcn.1602127
Keywords
This article is cited by
-
Effects of inulin supplementation on body composition and metabolic outcomes in children with obesity
Scientific Reports (2022)
-
Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
Microbiome (2021)
-
Treatment of non-alcoholic fatty liver disease — Current perspectives
Indian Journal of Gastroenterology (2020)
-
The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease
Current Hepatology Reports (2020)
-
Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose–response meta-analysis of 33 randomized controlled trials
Journal of Translational Medicine (2019)